AmCell

AmCell (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company dedicated to the development of innovative cell therapies for hematological malignancies and autoimmune diseases. The company utilizes its proprietary cell engineering and manufacturing platforms to create high-potency chimeric antigen receptor T-cell (CAR-T) therapies. Its lead candidate, AC001, is a CD19-targeted CAR-T therapy currently in Phase 2 clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma. Additionally, AmCell is advancing a pipeline of next-generation candidates, including BCMA-targeted therapies for multiple myeloma and multi-specific CAR-Ts to overcome tumor heterogeneity. The company is headquartered in Shanghai and maintains integrated R&D and GMP manufacturing capabilities to support its clinical programs.